ZAVEGEPANT (ZAVZPRET)
What to know about ZAVEGEPANT — also sold as ZAVZPRET: uses, side effects, interactions, and safety considerations for people taking it or caring for someone who is.
ZAVEGEPANT (brand names: ZAVZPRET) is classified as Low risk (2 risk points) by AllMeds. It is a S4 medication under the TGA in Australia. FDA approved in the United States. CGRP receptor antagonist for migraine with moderate systemic effects.
Key Takeaways
- TGA Schedule: S4 in Australia
- Risk level: Low (2 points)
Scheduling and Classification
| Jurisdiction | Classification | Status |
|---|---|---|
| Australia (TGA) | S4 | Not PBS listed |
| United States (FDA) | Rx only | FDA approved |
Risk Profile
CGRP receptor antagonist for migraine with moderate systemic effects.
How ZAVEGEPANT is regulated
ZAVEGEPANT is overseen by medicines regulators in each country. The rules below explain how it's scheduled, what oversight applies, and what to discuss with your doctor or pharmacist before starting, changing, or stopping this medication.
Australia TGA / PBS / State Schemes
Classified as S4 under the Therapeutic Goods Administration (TGA).
United States FDA / CDC / State WC
FDA approved for use in the United States.
Check this medication against your full medication list
Run a full risk assessment including ZAVEGEPANT interactions and compliance checks.
Allmeds AI Pharmacist scans interactions, schedules, and risk flags across your entire medication profile in minutes. Free for individuals; team plans for case managers, insurers, and schemes.
Important: This page is general health information, not personal medical advice. If you have questions about your medication — including starting it, stopping it, changing the dose, or combining it with something else — speak with your doctor or pharmacist. For an emergency or suspected overdose, call your local emergency number or poison information service immediately. Information is drawn from regulator and clinical guideline sources (TGA, FDA, MHRA, NICE, PBS, CDC); see our methodology for details.